4-((3-Pyridinylcarbonyl)amino)butanoic acid
Pikamilone · PIKAMILON · PICAMILON · Pikamiline · PikamiloneHCl · Picamilon >PICAMILON BASE · NICOTINOYL-GABA · N-Nicotinoyl-GABA
Identifiers & Physical Properties
| CAS No. | 34562-97-5 |
|---|---|
| Molecular formula | C10H12N2O3 |
| Average molar mass | 208.21 g/mol |
| Monoisotopic mass | 208.08479225 g/mol |
| SMILES | O=C(O)CCCNC(=O)c1cccnc1 |
| InChIKey | NAJVRARAUNYNDX-UHFFFAOYSA-N |
| PubChem CID | 60608 |
| ChEMBL | CHEMBL4303255 |
| EC No. | 609-002-1 |
| DTXSID | DTXSID40188098 |
Chemical & Physical Properties
| XLogP | -0.4 |
|---|---|
| Topological polar surface area | 79.3 |
| Hydrogen bond donors | 2 |
| Hydrogen bond acceptors | 4 |
| Rotatable bonds | 5 |
| Heavy atoms | 15 |
| Formal charge | 0 |
| Complexity | 231 |
| Melting point | 211.0 to 215.0 °C |
| Boiling point | 522.4±30.0 °C(Predicted) |
| Density | 1.245 |
| Storage conditions | Inert atmosphere,Room Temperature |
| Solubility | DMSO (Slightly, Heated), Methanol (Slightly) |
| Physical state | Solid |
| pKa (acidity coefficient) | 4.60±0.10(Predicted) |
| Color | White to Off-White |
| InChI | InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14) |
| InChIKey | NAJVRARAUNYNDX-UHFFFAOYSA-N |
| SMILES | C(O)(=O)CCCNC(C1=CC=CN=C1)=O |
| CAS DataBase Reference | 34562-97-5(CAS DataBase Reference) |
| FDA UNII | 0S5N9SEK4N |
| Hazard symbols | Xi |
| Hazard class | IRRITANT |
| Customs code | 2933599590 |
Safety & Regulations
| GHS classification | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%)Skin Irrit. 2 (100%)Eye Irrit. 2A (100%)STOT SE 3 (100%) |
| Customs code | 2933599590 |
| Hazard symbols | Xi |
| Hazard class | IRRITANT |
Applications & Uses
Description
Pikamilone is a drug having a central (vegetotropic and vascular) and peripheral (vasodilating) mechanisms of action.
Description
Picamilon: an analogue of the neurotransmitter γ-aminobutyric acid (GABA)Picamilon is a derivative of γ-aminobutyric acid (GABA) and nicotinic acid developed in 1970 by the All-Union Vitamin Research Institute to increase central nervous system (CNS) levels of γ-aminobutyric acid (GABA). Drugs that can mimic or increase GABA activity in the brain have the potential to provide anti-anxiety and anti-convulsive effects. GABA itself, when consumed orally, does not cross the blood-brain barrier. Much research has, therefore, been devoted to developing orally active agents that have GABA-like effects. Both gabapentin (a GABA analogue) and picamilon were designed to be orally administered drugs that cross the blood-brain barrier and provide inhibitory CNS effects. Picamilon, prescribed in dosages from 50 mg to 200 mg, can cross the blood-brain barrier in animal models and, once in the CNS, is hydrolyzed into GABA and nicotinic acid. The released GABA could potentially have inhibitory properties, including anti-anxiety and anti-convulsant effects. Nicotinic acid would also be released, potentially leading to dilation of CNS blood vessels. The FDA has never approved picamilon for use in the USA, but picamilon is used in Russia to treat various neurological conditions[1].
Uses
anti-cancer agent
Uses
Nicotinoyl-γ-aminobutyric Acid is a pro-drug of γ-Aminobutyric Acid (A602920). Studies show that Nicotinoyl-γ-aminobutyric Acid is involved in the regulation of the processes in the brain of streptozotocin-induced diabetic rats.